The biopharmaceutical company makes its debut on the Fortune 500 this year, riding the wave of a 49% year-over-year revenue increase in 2020—driven primarily by its cystic fibrosis drugs Kaftrio and Trikafta.
Lists ranking Vertex Pharmaceuticals
Latest news for Vertex Pharmaceuticals
- NewslettersVertex CEO takes an earnings victory lap right before he exitsJanuary 31, 2020 10:26 PM UTC
- NewslettersVertex’s $950 Million Bet on Stem Cells to Cure Diabetes: Brainstorm HealthSeptember 3, 2019 9:34 PM UTC
- HealthThis Biotech Just Gained Billions in Market Value Thanks to Its Cystic Fibrosis Drug CocktailJuly 19, 2017 8:15 PM UTC
- HealthThe FDA Wants Pharma to Ditch its Archaic Drug Making ProcessApril 14, 2016 8:52 PM UTC